Walleye Capital LLC Acquires Shares of 323,898 LifeMD, Inc. $LFMD

Walleye Capital LLC bought a new stake in shares of LifeMD, Inc. (NASDAQ:LFMD) during the second quarter, HoldingsChannel reports. The firm bought 323,898 shares of the company’s stock, valued at approximately $1,338,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new position in shares of LifeMD in the 4th quarter worth about $36,000. R Squared Ltd bought a new stake in LifeMD during the first quarter worth about $41,000. Jain Global LLC purchased a new stake in LifeMD in the fourth quarter worth about $45,000. Quarry LP purchased a new stake in LifeMD in the third quarter worth about $52,000. Finally, Tower Research Capital LLC TRC grew its holdings in LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares during the period. 35.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Zacks Research lowered shares of LifeMD from a “hold” rating to a “strong sell” rating in a report on Friday, July 17th. Wall Street Zen downgraded LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. UBS Group reaffirmed a “buy” rating on shares of LifeMD in a research report on Wednesday, May 27th. KeyCorp set a $5.00 price objective on LifeMD and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, BTIG Research dropped their target price on LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.57.

LifeMD News Summary

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate slightly to $(0.46) from $(0.47), increased its Q4 2026 estimate to $0.06 from $0.02, and improved its Q1 2027 estimate to $(0.07) from $(0.09). These revisions suggest the analyst sees some near-term improvement in profitability.
• Positive Sentiment: The continued Buy rating and $9.00 target indicate HC Wainwright believes LifeMD’s long-term valuation and growth prospects remain attractive despite ongoing losses.
• Neutral Sentiment: HC Wainwright projects LifeMD will remain unprofitable in FY2026, with estimated EPS of $(0.46), before losses narrow to $(0.12) in FY2027. The forecast implies a gradual recovery rather than immediate sustained profitability.
• Negative Sentiment: The analyst cut its Q3 2026 EPS estimate sharply to $(0.15) from $(0.05), signaling expectations for weaker near-term results.
• Negative Sentiment: Forecasts for Q2 2027 and Q3 2027 were reduced to $(0.13) and $(0.09), respectively, while the FY2027 estimate fell substantially to $(0.12) from $(0.01). The broader downward revision suggests profitability may take longer to achieve than previously expected.

LifeMD Stock Performance

Shares of LFMD stock opened at $3.45 on Friday. The company has a market capitalization of $166.29 million, a price-to-earnings ratio of -68.99 and a beta of 2.02. LifeMD, Inc. has a one year low of $2.56 and a one year high of $7.32. The company’s 50-day moving average is $4.26 and its 200 day moving average is $3.96.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The firm had revenue of $47.28 million during the quarter, compared to analysts’ expectations of $49.16 million. LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%. As a group, research analysts predict that LifeMD, Inc. will post -0.37 earnings per share for the current fiscal year.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.